Who are Fulvestrant Prefilled Syringe's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HM11260C, CKD-843 dose#1, Placebo + fulvestrant, Rezvilutamide Tablets, Fulvestrant in combination with abemaciclib, CKD-701.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fulvestrant-prefilled-syringe.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fulvestrant Prefilled Syringe — Competitive Intelligence Brief

Fulvestrant Prefilled Syringe (Fulvestrant Prefilled Syringe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor degrader (SERD). Area: Oncology.

phase 3 Selective estrogen receptor degrader (SERD) Estrogen receptor alpha (ERα) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fulvestrant Prefilled Syringe (Fulvestrant Prefilled Syringe) — UNICANCER. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors in hormone receptor-positive breast cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Fulvestrant Prefilled Syringe TARGET	Fulvestrant Prefilled Syringe	UNICANCER	phase 3	Selective estrogen receptor degrader (SERD)	Estrogen receptor alpha (ERα)
HM11260C	HM11260C	Hanmi Pharmaceutical Company Limited	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
CKD-843 dose#1	CKD-843 dose#1	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Placebo + fulvestrant	Placebo + fulvestrant	Nanjing Chia-tai Tianqing Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Rezvilutamide Tablets	Rezvilutamide Tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)
Fulvestrant in combination with abemaciclib	Fulvestrant in combination with abemaciclib	Sermonix Pharmaceuticals Inc.	phase 3	Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination	Estrogen receptor (ER) and CDK4/CDK6
CKD-701	CKD-701	Chong Kun Dang Pharmaceutical	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor degrader (SERD) class)

AstraZeneca · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fulvestrant Prefilled Syringe — Competitive Intelligence Brief. https://druglandscape.com/ci/fulvestrant-prefilled-syringe. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab